CN113876788A - Salidroside hydrogel preparation and preparation method and application thereof - Google Patents
Salidroside hydrogel preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN113876788A CN113876788A CN202111271252.4A CN202111271252A CN113876788A CN 113876788 A CN113876788 A CN 113876788A CN 202111271252 A CN202111271252 A CN 202111271252A CN 113876788 A CN113876788 A CN 113876788A
- Authority
- CN
- China
- Prior art keywords
- salidroside
- quaternized
- preparation
- hydrogel
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 title claims abstract description 98
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 title claims abstract description 98
- 239000000017 hydrogel Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 229920002101 Chitin Polymers 0.000 claims abstract description 36
- 229920001661 Chitosan Polymers 0.000 claims abstract description 33
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 24
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims description 34
- 238000009472 formulation Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- 150000004804 polysaccharides Chemical class 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229960002086 dextran Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
- LTVDFSLWFKLJDQ-UHFFFAOYSA-N α-tocopherolquinone Chemical group CC(C)CCCC(C)CCCC(C)CCCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000005956 quaternization reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000035699 permeability Effects 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 201000004624 Dermatitis Diseases 0.000 description 12
- 206010070834 Sensitisation Diseases 0.000 description 10
- 230000008313 sensitization Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000004006 olive oil Substances 0.000 description 7
- 235000008390 olive oil Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 4
- 229920000045 Dermatan sulfate Polymers 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241001234523 Velamen Species 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000220284 Crassulaceae Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 241000997135 Rhodiola crenulata Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a salidroside hydrogel preparation as well as a preparation method and application thereof. Specifically, the invention provides an application of salidroside in preparation of a drug for treating atopic dermatitis. The invention also provides a salidroside hydrogel preparation, which comprises salidroside, a cross-linking agent, and quaternized chitin or quaternized chitosan. The salidroside hydrogel preparation provided by the invention has the advantages of uniform and fine shape, stable property, safety and effectiveness, and can be applied to dermatology for treating atopic dermatitis. The invention also provides a preparation method of the salidroside hydrogel preparation. The process is simple, and the obtained salidroside hydrogel preparation has good storage stability; the hydrogel preparation of the invention has no irritation and allergy, good absorbability and high safety. The salidroside hydrogel preparation has good transdermal permeability.
Description
Technical Field
The invention relates to the field of medicinal preparations, in particular to a salidroside hydrogel preparation as well as a preparation method and application thereof.
Background
Salidroside is a compound extracted from dried root and rhizome or whole plant of rhodiola crenulata belonging to Crassulaceae, and has effects of preventing tumor, enhancing immunity, delaying aging, relieving fatigue, resisting anoxia, preventing radiation, regulating central nerve repair, repairing and protecting organism.
Atopic dermatitis (Atopic dermatitis) is a skin disease that has a genetic predisposition and recurrent attacks. In recent years, the incidence of AD in countries around the world tends to increase year by year, and the results of pathological investigation show that the incidence of AD in children is as high as 8.7% -18.1%, but not so, the incidence of AD in adults also tends to increase year by year, and has reached 2.1% -4.9%. The onset of AD is often accompanied by severe itching, which easily causes skin infection and seriously affects the life quality of patients. At present, glucocorticoid, calcineurin inhibitor and antibiotic are mainly used for treatment clinically, but the treatment side effects are large. For example, prolonged glucocorticoid administration can lead to various complications such as increased blood pressure, increased blood sugar, and necrosis of femoral head. Therefore, the development, research and application of anti-inflammatory drugs are one of the research hotspots in the field of dermatological drug therapeutics nowadays.
At present, salidroside is reported to have the effects of resisting aging and whitening skin in dermatology, and Zebrian blue is used for experimental analysis of salidroside and ginsenoside Rb1The effect of resisting skin photoaging is found that salidroside and ginsenoside Rb1Increasing the activity of SOD, Catalase (CAT) and Glutathione (GSH) in cells, and reducing the generation of Malondialdehyde (MDA), which suggests that salidroside can effectively resist skin photoaging. In addition, the research results show that salidroside has the effects of resisting radiation and skin melanoma. Yangliang research proves that salidroside has effects of inhibiting invasion and migration of human skin melanoma cell A375, and is used for resisting skinAspects of melanoma provide a basis.
In addition, salidroside is still mainly orally taken at present in clinical application, including tablets, capsules, injections and the like. However, the bioavailability is low because the drug is degraded in the gastrointestinal tract when orally administered. Therefore, the traditional administration mode of the salidroside is not an ideal administration mode of the dermatological drug, so that the research on a new dosage form changes the administration route of the salidroside and increases the treatment effect of locally treating the atopic dermatitis.
Therefore, there is a need for a drug effective in treating atopic dermatitis.
Disclosure of Invention
The present invention is directed to solving at least some of the problems of the prior art, and in a first aspect of the invention, the present invention provides a use of salidroside in the preparation of a medicament for treating atopic dermatitis.
The structural formula of the salidroside is shown as follows:
the salidroside is one of dry root or rhizome of rhodiola crenulata (Crassulaceae) or compound extracted from dry whole plant.
In a second aspect of the present invention, the present invention provides a salidroside hydrogel formulation comprising salidroside, a cross-linking agent, quaternized chitin or quaternized chitosan.
In one or more embodiments of the invention, the mass fraction of salidroside in the salidroside hydrogel preparation is 0.05-10%.
In one or more embodiments of the invention, the strength of the salidroside hydrogel ranges from 100 to 10000Pa, preferably 1700 Pa. The hydrogel formulations vary in intensity values over a wide range, and can achieve better state and properties. When the strength of the hydrogel formulation is less than 10Pa, the hydrogel is not easily immobilized externally; when the strength is more than 5000Pa, the skin coupling property of the hydrogel preparation is deteriorated, and the percutaneous permeability of salidroside is influenced. The hydrogel preparation has glittering and translucent appearance and smooth hand feeling, the rheological property of the preparation meets the requirement of practical application, and the preparation has good absorptivity, and can be used as a novel preparation for transdermal drug delivery of salidroside.
In a third aspect of the present invention, the present invention provides a method for preparing a salidroside hydrogel formulation according to the second aspect of the present invention, comprising the steps of:
step 1): preparing quaternized chitin or quaternized chitosan: carrying out homogeneous reaction on chitin or chitosan and a quaternization reagent in an alkali/urea system to obtain quaternized chitin or quaternized chitosan;
step 2): preparation of the crosslinking agent: carrying out oxidation reaction on natural polysaccharide to obtain a cross-linking agent;
step 3): preparing a quaternized chitin or quaternized chitosan solution: dissolving the quaternized chitin or quaternized chitosan prepared in the step 1) in Phosphate Buffer Solution (PBS) to obtain quaternized chitin or quaternized chitosan solution;
step 4): preparation of salidroside solution: dissolving the cross-linking agent obtained in the step 2) in water to prepare a cross-linking agent solution, and adding salidroside into the cross-linking agent solution to obtain a salidroside solution;
step 5): preparation of salidroside hydrogel formulation: uniformly mixing the quaternized chitin or quaternized chitosan solution obtained in the step 3) with the salidroside solution obtained in the step 4) to obtain the salidroside hydrogel preparation.
In one or more embodiments of the invention, in the step 1), the alkali is selected from one or two of sodium hydroxide and potassium hydroxide, and preferably, the homogeneous reaction temperature is controlled to be 25-40 ℃; preferably, the molar ratio of the quaternizing agent to the chitin unit is 4: 1; preferably, the quaternizing agent is 3-chloro-2-hydroxypropyltrimethylammonium chloride.
In one or more embodiments of the present invention, in the step 2), the natural polysaccharide is selected from one or more of dextran, alginic acid and hyaluronic acid.
In one or more embodiments of the present invention, in the step 2), the oxidation reaction includes: dissolving natural polysaccharide in water, adding NaIO4Stirring the aqueous solution away from light for reaction, stopping the reaction by using ethylene glycol, dialyzing and drying.
In one or more embodiments of the present invention, in the step 3), the concentration of the quaternized chitin or quaternized chitosan solution is controlled to be 0.5-10% (w/v).
In one or more embodiments of the present invention, in the step 4), the concentration of the cross-linking agent solution is controlled to be 0.5-10% (w/v); preferably, the concentration of the salidroside solution is controlled to be 1-10% (w/v).
In one or more embodiments of the present invention, in the step 5), the quaternized chitin or quaternized chitosan solution obtained in the step 3) and the salidroside solution obtained in the step 4) are mixed in equal volume.
In a third aspect of the invention, the invention provides a use of the salidroside hydrogel formulation of the second aspect of the invention in the preparation of a medicament for treating atopic dermatitis.
Compared with the prior art, the invention has the following advantages and beneficial effects:
1. the invention provides application of salidroside in preparation of a medicament for treating atopic dermatitis. The salidroside hydrogel preparation has uniform and fine shape, stable property, safety and effectiveness, and can be used for treating atopic dermatitis in dermatology.
2. The invention provides a preparation method of a salidroside hydrogel preparation, which has simple process, and the obtained salidroside hydrogel preparation has good storage stability; the hydrogel preparation of the invention has no irritation and allergy, good absorbability and high safety. The salidroside hydrogel preparation has good transdermal permeability.
Drawings
FIG. 1 is a graph comparing the results of morphological observations of healing of atopic dermatitis in mice treated with Normal group (Normal), model group (DNFB), commercial 999 dermatan-positive drug group (DEX), and salidroside hydrogel formulation (SDS);
FIG. 2 is a graph of H & E results of the Normal group (Normal), model group (DNFB), commercial 999 dermatan positive drug group (DEX), and salidroside hydrogel formulation (SDS) for the treatment of atopic dermatitis in mice;
FIG. 3 is a graph showing the comparison of TNF- α levels in atopic dermatitis in mice treated with Normal group (Normal), model group (DNFB), commercial 999 Dermatophagoides bengalensis positive drug group (DEX), and Salidroside hydrogel formulation (SDS);
FIG. 4 is a graph showing the results of comparing the levels of interleukin-6 in the Normal group (Normal), model group (DNFB), commercial 999 dermatan-positive drug group (DEX), and salidroside hydrogel formulation (SDS) for the treatment of atopic dermatitis in mice.
Detailed Description
The scheme of the invention will be explained with reference to the examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the invention only and should not be taken as limiting the scope of the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The methods used are conventional methods known in the art unless otherwise specified, and the consumables and reagents used are commercially available unless otherwise specified. Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
Example 1
The preparation method of the quaternized chitin or the quaternized chitosan comprises the following steps:
preparing 98g of an aqueous solution containing 20 wt% of KOH and 4 wt% of urea, precooling to-30 ℃, adding 2g of chitin or chitosan at room temperature, and mechanically stirring for 30 minutes to obtain a transparent and clear 2 wt% chitin or chitosan solution; adding 3-chloro-2-hydroxypropyl trimethyl ammonium chloride into the obtained chitin or chitosan solution to ensure that the molar ratio of a quaternizing agent (3-chloro-2-hydroxypropyl trimethyl ammonium chloride) to chitin units is 4:1, stirring for 24 hours, and adding HCl to neutralize the reaction solution; dialyzing the reaction solution by distilled water for 7 days, and freeze-drying to obtain the white fibrous quaternized chitin or quaternized chitosan.
The quaternized chitin or quaternized chitosan is prepared according to the method, and experimental groups 1-12 are implemented, wherein the preparation condition difference points of the experimental groups 1-12 and the properties of the obtained quaternized chitin or quaternized chitosan are shown in the following table 1.
Table 1 Experimental groups 1-12 for preparing quaternized chitin or quaternized chitosan condition difference points and properties of obtained quaternized chitin or quaternized chitosan
Example 2
The preparation method of the cross-linking agent comprises the following steps: the cross-linking agent is prepared by oxidation reaction of natural polysaccharide (dextran, sodium alginate and hyaluronic acid), and comprises the following specific steps: dissolving natural polysaccharides (dextran, sodium alginate and hyaluronic acid) in 150mL of water to obtain a polysaccharide solution with a certain concentration of 1-5 (w/v)%, dropwise adding NaIO4 dissolved in 10mL of water in advance, stirring for 2h in the dark, adding 0.4mL of glycol to terminate the reaction, continuously stirring for 1h, dialyzing, and freeze-drying to obtain oxidized polysaccharides, namely the cross-linking agent.
Oxidized polysaccharides were prepared according to the above method, with the differences shown in table 2 below.
TABLE 2 Experimental groups 1-12 the differences in the conditions for preparing oxidized polysaccharides and the properties of the oxidized polysaccharides obtained
Example 3
The preparation of the salidroside hydrogel formulation was as follows: the chitin quaternary ammonium salt or the chitosan quaternary ammonium salt obtained in the embodiment 1 is dissolved in Phosphate Buffer Solution (PBS) to prepare chitin quaternary ammonium salt or chitosan quaternary ammonium salt solution with the concentration of 0.5-10% (w/v), and then the concentration of the oxidized polysaccharide prepared in the embodiment 2 is determined according to the proportion of aldehyde groups and amino functional groups to prepare solution with the concentration of 0.5-10% (w/v). Dissolving salidroside in an oxidized polysaccharide aqueous solution at a certain concentration, wherein the concentration of salidroside is 1-10% (w/v), and mixing the quaternized chitin or quaternized chitosan solution and the oxidized polysaccharide solution containing salidroside in equal volume to obtain the salidroside hydrogel preparation.
Salidroside hydrogel formulations were prepared according to the above method, with the differences in preparation conditions as shown in table 3 below.
Table 3 different points of conditions for preparing salidroside hydrogel preparation and properties of obtained salidroside hydrogel preparation in experimental groups 1-12
Example 4
Evaluation of Properties
Pharmacodynamic evaluation of treatment of atopic dermatitis in mice
The salidroside hydrogel preparation has good therapeutic effect on atopic dermatitis with little side effect. In this example, the salidroside hydrogel preparation prepared in experimental group 5 of example 3 was used as an external preparation, and by establishing a mouse atopic dermatitis animal model, the salidroside hydrogel preparation prepared in the present invention was compared with the commercially available 999 compound for treating dermatitis (positive drug), and it was desired to develop a novel and effective external preparation for treating skin inflammation.
Test materials and methods
Experimental reagent: 2, 4 dinitrofluorobenzene (DNFB, tokyo chemical industries co., ltd.); acetone (Shanghai Bide pharmaceutical science Co., Ltd.); olive oil (shanghai alatin Biotechnology, ltd.); 999 dermatitis remedy (Huarun sanjiu medicine, ltd); salidroside (Shanghai Bide pharmaceutical science Co., Ltd.).
Electronic instrumentation (ai rui trade, inc. of yongkang); pet razor (Ningbo Aikelipi electric appliance Co., Ltd.)
Experimental animals: mouse (BALB/c, male, 18 ~ 22g, university of three gorges animal experiment center)
Establishment of mouse atopic dermatitis model: one day before the experiment, the hair on the back of the mouse is removed by an electric shaver, and the mouse is smeared with vetting depilatory cream and then wiped clean by physiological saline. The induction was performed in a concentration decreasing manner, using 0.5% DNFB followed by 0.2% DNFB. Sensitization was carried out with 100. mu.L of 0.5% DNFB (acetone: olive oil 4: 1) at intervals of one day, and on the third day, sensitization was carried out by continuously applying 100. mu.L of 0.5% DNFB (acetone: olive oil 4: 1) to the back of the mouse, and sensitization was boosted on the fourth day. Dosing was started 2h after the third sensitization. After three days, 100. mu.L of DNFB (acetone: olive oil: 4: 1) was applied to the back of the mouse at the eighth day of molding to induce sensitization, and then sensitization was performed again at 5 days. The injury condition of the back of the mouse is recorded by taking pictures every two days.
Experimental grouping and dosing: normal group acetone was applied to the area of the back epilation: the olive oil is 4:1, once a day. The processing nodes are the same as the group.
Model group: the first day of the experiment, 100 μ L of DNFB (acetone: olive oil 4: 1) was applied to the back of the mouse at intervals of one day, and then the third day of the experiment, the sensitization was enhanced. Dosing was started 2h after the third sensitization. After three days, 100. mu.L of DNFB (acetone: olive oil: 4: 1) was applied to the back of the mouse at the eighth day of molding to induce sensitization, and then sensitization was performed again at 5 days. The injury condition of the back of the mouse is recorded by taking pictures every two days.
Dexamethasone (999 commercial Pingyang drug for dermatitis), the node and operation mode of back molding of mice are the same as those of the model group, and the model is molded while the administration treatment is carried out at the dose of 0.1mg/kg every day. Is taken in the morning and at night.
2.5% salidroside hydrogel group (salidroside hydrogel formulation prepared in experimental group 5 of example 3): the node and operation mode of the mouse back molding are the same as those of the model group, and the salidroside hydrogel preparation is smeared on the back of the mouse for treatment during molding. Is taken in the morning and at night.
Evaluation method
1. Morphological observation of wound healing
H & E staining
TNF-alpha, interleukin-6
Results of the experiment
FIG. 1 is a graph showing the comparison of the results of morphological observation of the healing of atopic dermatitis in mice treated with Normal group (Normal), model group (DNFB), commercial 999 dermatitides-positive group (DEX), and rhodioside hydrogel formulation (SDS) (the rhodioside hydrogel formulation prepared in Experimental group 5 of example 3); as can be seen from figure 1, the salidroside hydrogel preparation and the commercial 999 dermatitis velamen administration show that the morphological observation of the healing of the dermatitis in figure 1 shows that the salidroside hydrogel preparation group and the 999 dermatitis velamen group have the effect of treating the atopic dermatitis, but the effect of the salidroside hydrogel group is better than that of the 999 dermatitis velamen group, the salidroside hydrogel group is found to accelerate the exfoliation caused by the skin damage in the experiment, the skin of the salidroside hydrogel group is obviously recovered faster than that of the 999 dermatitis velamen group, and the skin is more moist.
FIG. 2 is a graph of H & E results of treatment of atopic dermatitis in mice with Normal group (Normal), model group (DNFB), commercial 999 dermatan positive drug group (DEX), and salidroside hydrogel formulation (SDS); as can be seen from fig. 2, the expressions of granulocytes, monocytes, macrophages and lymphocytes in the model group were significantly increased compared to the normal group, and the inflammatory cells such as granulocytes, monocytes and macrophages in the SDS group treated with the salidroside hydrogel preparation prepared by the present invention were significantly decreased compared to the model group. The dexamethasone ointment group (the commercial 999 dermatitis Pingyang drug group) also has reduced expression of various inflammatory cells.
FIGS. 3 and 4 are graphs showing the comparison results of TNF-alpha and interleukin-6 levels in the Normal group (Normal), model group (DNFB), commercial 999 dermatidine positive drug group (DEX) and salidroside hydrogel preparation (SDS) for treating atopic dermatitis of mice, respectively, and it can be seen that the TNF-alpha and IL-6 levels in the salidroside hydrogel group prepared by the present invention are significantly reduced compared with the model group.
The experimental results show that the salidroside hydrogel preparation developed by the invention is uniformly smeared on the focus part twice a day by percutaneous administration, and obtains satisfactory curative effect after 2 weeks, and compared with the 999 positive medicament, the salidroside hydrogel preparation prepared by the invention has better curative effect than the 999 positive medicament sold on the market for dermatitis.
Although the embodiments of the present invention have been shown and described, it is understood that the above embodiments are illustrative and not restrictive, and that those skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention and that the present invention also includes the modifications and changes.
Claims (10)
1. Application of salidroside in preparing medicine for treating atopic dermatitis is provided.
2. A salidroside hydrogel preparation is characterized by comprising salidroside, a cross-linking agent, and quaternized chitin or quaternized chitosan.
3. The salidroside hydrogel formulation according to claim 2, wherein the mass fraction of salidroside in the salidroside hydrogel formulation is 0.05-10%; preferably, the strength range of the salidroside hydrogel is 100-10000 Pa, and 1700Pa is preferable.
4. A method for producing the salidroside hydrogel formulation of claim 2 or claim 3, comprising the steps of:
step 1): preparing quaternized chitin or quaternized chitosan: carrying out homogeneous reaction on chitin or chitosan and a quaternization reagent in an alkali/urea system to obtain quaternized chitin or quaternized chitosan;
step 2): preparation of the crosslinking agent: carrying out oxidation reaction on natural polysaccharide to obtain a cross-linking agent;
step 3): preparing a quaternized chitin or quaternized chitosan solution: dissolving the quaternized chitin or quaternized chitosan prepared in the step 1) in Phosphate Buffer Solution (PBS) to obtain quaternized chitin or quaternized chitosan solution;
step 4): preparation of salidroside solution: dissolving the cross-linking agent obtained in the step 2) in water to prepare a cross-linking agent solution, and adding salidroside into the cross-linking agent solution to obtain a salidroside solution;
step 5): preparation of salidroside hydrogel formulation: uniformly mixing the quaternized chitin or quaternized chitosan solution obtained in the step 3) with the salidroside solution obtained in the step 4) to obtain the salidroside hydrogel preparation.
5. The method for preparing the salidroside hydrogel formulation according to claim 4, wherein in the step 1), the alkali is selected from one or two of sodium hydroxide and potassium hydroxide, and preferably, the homogeneous reaction temperature is controlled to be 25-40 ℃; preferably, the molar ratio of the quaternizing agent to the chitin unit is 4: 1; preferably, the quaternizing agent is 3-chloro-2-hydroxypropyltrimethylammonium chloride.
6. The method for preparing the salidroside hydrogel formulation as claimed in claim 4, wherein in step 2), the natural polysaccharide is selected from one or more of dextran, alginic acid and hyaluronic acid; preferably, the oxidation reaction comprises: dissolving natural polysaccharide in water, adding NaIO4Stirring the aqueous solution away from light for reaction, stopping the reaction by using ethylene glycol, dialyzing and drying.
7. The method for preparing the salidroside hydrogel formulation according to claim 4, wherein in step 3), the concentration of the quaternized chitin or quaternized chitosan solution is controlled to be 0.5-10% (w/v).
8. The method for preparing the salidroside hydrogel formulation according to claim 4, wherein in said step 4), the concentration of said cross-linking agent solution is controlled to be 0.5-10% (w/v); preferably, the concentration of the salidroside solution is controlled to be 1-10% (w/v).
9. The method for preparing the salidroside hydrogel formulation according to claim 4, wherein in step 5), the quaternized chitin or quaternized chitosan solution obtained in step 3) and the salidroside solution obtained in step 4) are mixed in equal volume.
10. Use of the salidroside hydrogel formulation of claim 2 or claim 3 for the preparation of a medicament for treating atopic dermatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111271252.4A CN113876788B (en) | 2021-10-29 | 2021-10-29 | Rhodiola rosea glycoside hydrogel preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111271252.4A CN113876788B (en) | 2021-10-29 | 2021-10-29 | Rhodiola rosea glycoside hydrogel preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113876788A true CN113876788A (en) | 2022-01-04 |
| CN113876788B CN113876788B (en) | 2023-12-08 |
Family
ID=79014502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111271252.4A Active CN113876788B (en) | 2021-10-29 | 2021-10-29 | Rhodiola rosea glycoside hydrogel preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113876788B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115634240A (en) * | 2022-09-29 | 2023-01-24 | 西藏大学 | Luteolin green algae hydrogel preparation and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748493A (en) * | 2016-03-24 | 2016-07-13 | 史飞 | Application of salidroside in prevention and/or treatment of skin inflammation caused by abnormal increase of COX-2 activity through inhibition of cyclooxygenase-2(COX-2) |
| CN109293948A (en) * | 2018-08-10 | 2019-02-01 | 广东省医疗器械研究所 | A kind of hydrogel and its preparation method and application |
| CN109593213A (en) * | 2018-11-26 | 2019-04-09 | 西安理工大学 | A kind of preparation method of high intensity hydrogel |
| CN112225909A (en) * | 2020-09-21 | 2021-01-15 | 广东医科大学附属医院 | Salidroside-chitosan hydrogel composite material and preparation method and application thereof |
| CN112773942A (en) * | 2019-11-04 | 2021-05-11 | 武汉大学 | Preparation method of injectable self-healing antibacterial hydrogel |
-
2021
- 2021-10-29 CN CN202111271252.4A patent/CN113876788B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748493A (en) * | 2016-03-24 | 2016-07-13 | 史飞 | Application of salidroside in prevention and/or treatment of skin inflammation caused by abnormal increase of COX-2 activity through inhibition of cyclooxygenase-2(COX-2) |
| CN109293948A (en) * | 2018-08-10 | 2019-02-01 | 广东省医疗器械研究所 | A kind of hydrogel and its preparation method and application |
| CN109593213A (en) * | 2018-11-26 | 2019-04-09 | 西安理工大学 | A kind of preparation method of high intensity hydrogel |
| CN112773942A (en) * | 2019-11-04 | 2021-05-11 | 武汉大学 | Preparation method of injectable self-healing antibacterial hydrogel |
| CN112225909A (en) * | 2020-09-21 | 2021-01-15 | 广东医科大学附属医院 | Salidroside-chitosan hydrogel composite material and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 方燕: "甲壳素/壳聚糖在碱/尿素体系中的溶解机理及溶液性质研究", 博士学位论文工程科技Ⅰ辑, pages 4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115634240A (en) * | 2022-09-29 | 2023-01-24 | 西藏大学 | Luteolin green algae hydrogel preparation and preparation method and application thereof |
| CN115634240B (en) * | 2022-09-29 | 2024-07-02 | 西藏大学 | Luteolin green algae hydrogel preparation and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113876788B (en) | 2023-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7648968B2 (en) | Methods of treating dermal ulcers using glucans | |
| CN110431154B (en) | Hyaluronic acid cross-linked with natural or semi-synthetic cross-linking agents | |
| JPH0873342A (en) | Skin external preparation or bathing agent containing rubi fructus extract | |
| JP2014231487A (en) | Sirtuin gene activator containing shell membrane component and composition using thereof | |
| CN113876788A (en) | Salidroside hydrogel preparation and preparation method and application thereof | |
| Baraldi et al. | Dermocosmetic Applications of Polymeric Biomaterials | |
| CN110917120A (en) | Sticky antibacterial repairing material and preparation method and application thereof | |
| KR100796904B1 (en) | Compositions for promoting hair growth containing complexes of stabilized Vitamin C or Vitamin C derivatives | |
| JP3998085B2 (en) | Hyaluronic acid amount increase accelerator | |
| CN104053425B (en) | Medical science skin care compositions based on collargol and the synergistic combination of DNA (deoxyribonucleic acid) | |
| KR20230051105A (en) | Composition for growth promotion and proliferation of hair comprising a hydrolyzed DNA fragment mixture as an active ingredient | |
| CN112773816B (en) | Wound repair spray and preparation method and application thereof | |
| CN1401365A (en) | Chinese health medicine | |
| Mora et al. | Dermocosmetic applications of polymeric biomaterials | |
| CN113230154A (en) | Composition with anti-allergy, relieving and anti-inflammation effects and preparation method and application thereof | |
| KR960011231B1 (en) | Human leukocyte interferon composition | |
| WO2017088177A1 (en) | Mussel adhesive protein product, and use thereof in preventing and suppressing neuronal inflammation | |
| JP2005112762A (en) | Skin care preparation for external use | |
| CN114053329B (en) | Application of broussonetia papyrifera polysaccharide in preparation of medicines or sunscreen cosmetics for preventing and treating ultraviolet injury | |
| CN114177301B (en) | Composition containing tranexamic acid and application of composition in preparation of medicines for treating chloasma | |
| KR20140114921A (en) | Aloe composition for moisturizing the skin | |
| JP2000119126A (en) | Effective composition for vital environment | |
| RU2092156C1 (en) | Solution for skin repair stimulation | |
| BR102021012762A2 (en) | BIOCAUTIVES CONTAINING EXTRACT OR POLYSACCHARIDES OF THE MUSHROOM AGARICUS BRASILIENSIS FOR THE TREATMENT OF WOUNDS | |
| CN117860604A (en) | Application of xylooligosaccharide in preparation of skin pore improving and anti-aging skin care product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |